name: "Eylea Literature-Based Parameters"
description: "Evidence-based parameters derived from ALTAIR, VIEW 1/2, Mylight, and other studies"
version: "1.0"

protocol_specific:
  clinical_model:
    disease_states:
      - NAIVE
      - STABLE
      - ACTIVE
      - HIGHLY_ACTIVE
    
    # Transition probabilities based on ALTAIR study and other literature
    transition_probabilities:
      NAIVE:
        NAIVE: 0.0
        STABLE: 0.58  # From ALTAIR
        ACTIVE: 0.32  # From ALTAIR
        HIGHLY_ACTIVE: 0.10  # From ALTAIR
      STABLE:
        STABLE: 0.83  # From ALTAIR
        ACTIVE: 0.12  # From ALTAIR
        HIGHLY_ACTIVE: 0.05  # From ALTAIR
      ACTIVE:
        STABLE: 0.32  # From ALTAIR
        ACTIVE: 0.57  # From ALTAIR
        HIGHLY_ACTIVE: 0.11  # From ALTAIR
      HIGHLY_ACTIVE:
        STABLE: 0.08  # From ALTAIR (estimated)
        ACTIVE: 0.34  # From ALTAIR (estimated)
        HIGHLY_ACTIVE: 0.58  # From ALTAIR (estimated)
    
    # Vision change parameters based on literature evidence
    vision_change:
      base_change:
        NAIVE:
          injection: [8.4, 1.3]  # Mean letter change, SD from ALTAIR/VIEW studies
          no_injection: [-2.5, 1.0]  # Estimated from literature
        STABLE:
          injection: [1.5, 0.7]  # From ALTAIR
          no_injection: [-0.75, 0.5]  # From ALTAIR
        ACTIVE:
          injection: [0.8, 0.7]  # From ALTAIR
          no_injection: [-1.5, 1.0]  # From ALTAIR
        HIGHLY_ACTIVE:
          injection: [0.3, 1.2]  # From ALTAIR
          no_injection: [-4.0, 1.5]  # From ALTAIR
      
      time_factor:
        max_weeks: 16  # From ALTAIR pharmacokinetic studies
      
      ceiling_factor:
        max_vision: 85  # Typical ceiling in clinical studies
      
      measurement_noise: [0, 0.5]  # Test-retest variability
    
    # Treatment discontinuation parameters
    treatment_discontinuation:
      recurrence_probabilities:
        base_risk_per_year: 0.207  # 1-year recurrence rate (Artiaga et al.)
        cumulative_3_year: 0.739  # 3-year recurrence rate (Artiaga et al.)
        cumulative_5_year: 0.880  # 5-year recurrence rate (Artiaga et al.)
      
      recurrence_impact:
        vision_loss_letters: 3.6  # Mean vision loss at recurrence (Aslanis et al.)
        vision_recovery_factor: 0.95  # Proportion of vision recovered after retreatment
      
      symptom_detection:
        probability: 0.609  # Probability recurrence causes symptoms (Artiaga et al.)
        detection_sensitivity: 1.0  # Probability symptoms lead to detection
      
      monitoring_schedule:
        year_1: 12  # Weeks between monitoring visits in year 1
        year_2_3: 16  # Weeks between monitoring visits in years 2-3
        year_4_plus: 24  # Weeks between monitoring visits after year 3
  
  treatment_response:
    loading_phase:
      vision_improvement_mean: 8.4  # From ALTAIR, VIEW 1/2, Mylight
      vision_improvement_sd: 1.3
      treatment_response_factor: 1.0
      improve_probability: 0.80
      stable_probability: 0.15
      decline_probability: 0.05
      decline_mean: -2.0
      decline_sd: 1.0
    
    maintenance_phase:
      vision_stability_threshold: 5
      disease_recurrence_base_risk: 0.15  # Based on ALTAIR
      risk_increase_per_week: 0.01
      decline_probability: 0.12  # Based on ALTAIR
      decline_effect_mean: -1.5
      decline_effect_sd: 0.7
      memory_factor: 0.7
      base_effect_ceiling: 5
      regression_factor: 0.8
      random_effect_mean: 0.5
      random_effect_sd: 0.4
  
  # OCT parameters - limited data available
  oct_parameters:
    baseline_thickness_mean: 350  # Typical baseline CRT in wet AMD
    baseline_thickness_sd: 50
    treatment_effect_mean: 130  # Based on ALTAIR, VIEW 1/2 (~130Î¼m reduction)
    treatment_effect_sd: 20
    change_thresholds:
      high_risk: 50
      medium_risk: 25
    thickness_thresholds:
      high_risk: 300
      medium_risk: 275
    fluid_risk:
      beta_shape_a: 2
      beta_shape_b: 5
  
  vision:
    baseline_mean: 65  # Typical baseline in clinical trials
    baseline_sd: 10
    measurement_noise_sd: 2
    max_letters: 85
    min_letters: 0
    improvement_ceiling: 5
    headroom_factor: 0.2
  
  # Placeholder for resource parameters
  resources:
    doctors: 2
    nurses: 4
    oct_machines: 2
  
  # Cost parameters (placeholders)
  costs:
    visit_costs:
      standard_visit: 0
      injection_visit: 0
      imaging_visit: 0
      virtual_review: 0
    drug_costs:
      aflibercept_2mg: 0
    resource_utilization:
      time_per_standard_visit: 15  # minutes
      time_per_injection: 10  # additional minutes
      time_per_imaging: 15  # minutes
      time_per_virtual_review: 5  # minutes
